Harel Insurance Investments & Financial Services Ltd. Has $297.89 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Harel Insurance Investments & Financial Services Ltd. increased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 3.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 28,533,099 shares of the company's stock after buying an additional 821,759 shares during the period. Teva Pharmaceutical Industries accounts for 5.2% of Harel Insurance Investments & Financial Services Ltd.'s portfolio, making the stock its 3rd largest holding. Harel Insurance Investments & Financial Services Ltd. owned 2.55% of Teva Pharmaceutical Industries worth $297,886,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in TEVA. Money Concepts Capital Corp acquired a new position in Teva Pharmaceutical Industries in the fourth quarter worth approximately $25,000. Tower Research Capital LLC TRC boosted its position in Teva Pharmaceutical Industries by 1,729.5% during the third quarter. Tower Research Capital LLC TRC now owns 3,787 shares of the company's stock worth $39,000 after purchasing an additional 3,580 shares during the period. Blue Trust Inc. boosted its position in Teva Pharmaceutical Industries by 92.3% during the fourth quarter. Blue Trust Inc. now owns 4,541 shares of the company's stock worth $46,000 after purchasing an additional 2,180 shares during the period. Signaturefd LLC boosted its position in Teva Pharmaceutical Industries by 90.8% during the third quarter. Signaturefd LLC now owns 5,032 shares of the company's stock worth $51,000 after purchasing an additional 2,394 shares during the period. Finally, UniSuper Management Pty Ltd bought a new stake in Teva Pharmaceutical Industries during the second quarter worth approximately $57,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA traded down $0.57 during mid-day trading on Friday, hitting $13.30. The company's stock had a trading volume of 15,238,796 shares, compared to its average volume of 7,262,766. Teva Pharmaceutical Industries Limited has a one year low of $7.09 and a one year high of $14.47. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02. The firm has a market capitalization of $14.91 billion, a PE ratio of -28.30, a price-to-earnings-growth ratio of 1.54 and a beta of 1.05. The stock's 50-day moving average is $13.41 and its two-hundred day moving average is $11.16.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.73 by $0.25. The firm had revenue of $4.46 billion during the quarter, compared to analysts' expectations of $3.97 billion. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.28 EPS for the current year.

Insider Buying and Selling

In related news, CAO Amir Weiss sold 31,766 shares of the firm's stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total value of $392,945.42. Following the completion of the transaction, the chief accounting officer now directly owns 10,676 shares of the company's stock, valued at $132,062.12. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Teva Pharmaceutical Industries news, VP Eric Drape sold 173,261 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the completion of the transaction, the vice president now directly owns 1 shares in the company, valued at $13.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Amir Weiss sold 31,766 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total value of $392,945.42. Following the transaction, the chief accounting officer now owns 10,676 shares of the company's stock, valued at $132,062.12. The disclosure for this sale can be found here. Insiders sold a total of 390,738 shares of company stock valued at $5,132,766 over the last ninety days. 0.62% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

TEVA has been the subject of a number of recent analyst reports. HSBC initiated coverage on Teva Pharmaceutical Industries in a research report on Monday, December 18th. They set a "buy" rating and a $13.00 target price for the company. Piper Sandler raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their target price for the stock from $12.00 to $19.00 in a research report on Monday, February 12th. The Goldman Sachs Group upped their target price on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a "neutral" rating in a research report on Monday, February 5th. Barclays upped their target price on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an "overweight" rating in a research report on Monday, February 5th. Finally, JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 price objective for the company in a research report on Friday, March 8th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $13.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.